Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia

Ian J. Welsby, John Y Um, Carmelo A. Milano, Thomas L. Ortel, Gowthami Arepally

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: Heparin-induced thrombocytopenia (HIT) complicates the management of patients presenting for cardiac surgery, because high-dose heparin anticoagulation for cardiopulmonary bypass is contraindicated in these patients. Alternative anticoagulants are available, but there are concerns about dosing, efficacy, monitoring, thrombosis, and hemorrhage. Methods: A retrospective chart review between November 2004 and March 2008 retrieved perioperative clinical and laboratory data for 11 adult cardiac surgical patients with a preoperative history of HIT and a current positive antiheparin/platelet factor 4 (anti-HPF4) antibody titer, who were managed with plasmapheresis and heparin anticoagulation. Results: The median (interquartile range) preoperative anti-HPF4 antibody titer was 0.8 (0.7-2.2). Three of the 11 patients (27%) died of causes unrelated to HIT and 1 of these patients (9%) developed an ischemic foot, in the setting of cardiogenic shock, not thought to be HIT-related. A single plasmapheresis treatment reduced titers by 50%-84%, and 6 patients had negative titers after treatment; none of the 3 patients with reduced titers developed clinical HIT. Conclusions: This case series describes an alternative management strategy using intraoperative plasmapheresis for patients presenting for cardiac surgery with acute or subacute HIT. Reducing antibody load can potentially decrease the thrombotic risk associated with high anti-HPF4 titers and decrease the urgency to initiate postoperative anticoagulation in this patient group at high risk of postoperative bleeding.

Original languageEnglish (US)
Pages (from-to)30-35
Number of pages6
JournalAnesthesia and analgesia
Volume110
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Plasmapheresis
Thrombocytopenia
Platelet Factor 4
Heparin
Thoracic Surgery
Antibodies
Hemorrhage
Cardiogenic Shock
Cardiopulmonary Bypass
Anticoagulants
Foot
Thrombosis

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. / Welsby, Ian J.; Um, John Y; Milano, Carmelo A.; Ortel, Thomas L.; Arepally, Gowthami.

In: Anesthesia and analgesia, Vol. 110, No. 1, 01.01.2010, p. 30-35.

Research output: Contribution to journalArticle

Welsby, Ian J. ; Um, John Y ; Milano, Carmelo A. ; Ortel, Thomas L. ; Arepally, Gowthami. / Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. In: Anesthesia and analgesia. 2010 ; Vol. 110, No. 1. pp. 30-35.
@article{b65bccdf17954f25ac73b7b2e2eed5cc,
title = "Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia",
abstract = "Background: Heparin-induced thrombocytopenia (HIT) complicates the management of patients presenting for cardiac surgery, because high-dose heparin anticoagulation for cardiopulmonary bypass is contraindicated in these patients. Alternative anticoagulants are available, but there are concerns about dosing, efficacy, monitoring, thrombosis, and hemorrhage. Methods: A retrospective chart review between November 2004 and March 2008 retrieved perioperative clinical and laboratory data for 11 adult cardiac surgical patients with a preoperative history of HIT and a current positive antiheparin/platelet factor 4 (anti-HPF4) antibody titer, who were managed with plasmapheresis and heparin anticoagulation. Results: The median (interquartile range) preoperative anti-HPF4 antibody titer was 0.8 (0.7-2.2). Three of the 11 patients (27{\%}) died of causes unrelated to HIT and 1 of these patients (9{\%}) developed an ischemic foot, in the setting of cardiogenic shock, not thought to be HIT-related. A single plasmapheresis treatment reduced titers by 50{\%}-84{\%}, and 6 patients had negative titers after treatment; none of the 3 patients with reduced titers developed clinical HIT. Conclusions: This case series describes an alternative management strategy using intraoperative plasmapheresis for patients presenting for cardiac surgery with acute or subacute HIT. Reducing antibody load can potentially decrease the thrombotic risk associated with high anti-HPF4 titers and decrease the urgency to initiate postoperative anticoagulation in this patient group at high risk of postoperative bleeding.",
author = "Welsby, {Ian J.} and Um, {John Y} and Milano, {Carmelo A.} and Ortel, {Thomas L.} and Gowthami Arepally",
year = "2010",
month = "1",
day = "1",
doi = "10.1213/ANE.0b013e3181c3c1cd",
language = "English (US)",
volume = "110",
pages = "30--35",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia

AU - Welsby, Ian J.

AU - Um, John Y

AU - Milano, Carmelo A.

AU - Ortel, Thomas L.

AU - Arepally, Gowthami

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background: Heparin-induced thrombocytopenia (HIT) complicates the management of patients presenting for cardiac surgery, because high-dose heparin anticoagulation for cardiopulmonary bypass is contraindicated in these patients. Alternative anticoagulants are available, but there are concerns about dosing, efficacy, monitoring, thrombosis, and hemorrhage. Methods: A retrospective chart review between November 2004 and March 2008 retrieved perioperative clinical and laboratory data for 11 adult cardiac surgical patients with a preoperative history of HIT and a current positive antiheparin/platelet factor 4 (anti-HPF4) antibody titer, who were managed with plasmapheresis and heparin anticoagulation. Results: The median (interquartile range) preoperative anti-HPF4 antibody titer was 0.8 (0.7-2.2). Three of the 11 patients (27%) died of causes unrelated to HIT and 1 of these patients (9%) developed an ischemic foot, in the setting of cardiogenic shock, not thought to be HIT-related. A single plasmapheresis treatment reduced titers by 50%-84%, and 6 patients had negative titers after treatment; none of the 3 patients with reduced titers developed clinical HIT. Conclusions: This case series describes an alternative management strategy using intraoperative plasmapheresis for patients presenting for cardiac surgery with acute or subacute HIT. Reducing antibody load can potentially decrease the thrombotic risk associated with high anti-HPF4 titers and decrease the urgency to initiate postoperative anticoagulation in this patient group at high risk of postoperative bleeding.

AB - Background: Heparin-induced thrombocytopenia (HIT) complicates the management of patients presenting for cardiac surgery, because high-dose heparin anticoagulation for cardiopulmonary bypass is contraindicated in these patients. Alternative anticoagulants are available, but there are concerns about dosing, efficacy, monitoring, thrombosis, and hemorrhage. Methods: A retrospective chart review between November 2004 and March 2008 retrieved perioperative clinical and laboratory data for 11 adult cardiac surgical patients with a preoperative history of HIT and a current positive antiheparin/platelet factor 4 (anti-HPF4) antibody titer, who were managed with plasmapheresis and heparin anticoagulation. Results: The median (interquartile range) preoperative anti-HPF4 antibody titer was 0.8 (0.7-2.2). Three of the 11 patients (27%) died of causes unrelated to HIT and 1 of these patients (9%) developed an ischemic foot, in the setting of cardiogenic shock, not thought to be HIT-related. A single plasmapheresis treatment reduced titers by 50%-84%, and 6 patients had negative titers after treatment; none of the 3 patients with reduced titers developed clinical HIT. Conclusions: This case series describes an alternative management strategy using intraoperative plasmapheresis for patients presenting for cardiac surgery with acute or subacute HIT. Reducing antibody load can potentially decrease the thrombotic risk associated with high anti-HPF4 titers and decrease the urgency to initiate postoperative anticoagulation in this patient group at high risk of postoperative bleeding.

UR - http://www.scopus.com/inward/record.url?scp=74049137868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049137868&partnerID=8YFLogxK

U2 - 10.1213/ANE.0b013e3181c3c1cd

DO - 10.1213/ANE.0b013e3181c3c1cd

M3 - Article

VL - 110

SP - 30

EP - 35

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 1

ER -